- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Nucleobindin 2 (NUCB2) in human endometrial carcinoma: a potent prognostic factor associated with cell proliferation and migration
-
- Takagi Kiyoshi
- Departments of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan
-
- Miki Yasuhiro
- Department of Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science, Tohoku University, Sendai, Japan
-
- Tanaka Sota
- Departments of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan
-
- Hashimoto Chiaki
- Departments of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan
-
- Watanabe Mika
- Department of Pathology, Tohoku University Hospital, Sendai, Japan
-
- Sasano Hironobu
- Departments of Anatomic Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan
-
- Ito Kiyoshi
- Department of Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science, Tohoku University, Sendai, Japan
-
- Suzuki Takashi
- Departments of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search this article
Description
Nucleobindin 2 (NUCB2) is a multifunctional protein containing several functional domains, and associated with wide variety of biological process such as food intake and energy homeostasis. Recently, NUCB2 has been implicated in not only normal human tissues but also some kinds of human malignancies. However, its clinical and/or biological significance has largely remained unknown in endometrial carcinomas. We therefore immunolocalized NUCB2 protein in 87 endometrial carcinoma tissues and examined its clinical significance. NUCB2 immunoreactivity was detected in 19 out of 87 (22%) of endometrial carcinoma cases examined, and positively correlated with Ki67 labeling index, while there was no significant correlation between NUCB2 and stage, histological grade, and progesterone receptor status. Furthermore, NUCB2 immunoreactivity was significantly correlated with increased risk of recurrence and worse clinical outcome regardless of stage or histological grade. Subsequent multivariate analyses did reveal that NUCB2 immunoreactivity was an independent prognostic factor for both disease-free survival and endometrial cancer specific survival. In vitro experiments demonstrated that knockdown of NUCB2 using specific siRNA for NUCB2 significantly impaired cell proliferation and migration of the endometrial carcinoma cell lines, Ishikawa and Sawano cells, and that nesfatin-1 treatment significantly promoted cell proliferation and migration in Ishikawa cells. These findings possibly suggested that NUCB2 and/or nesfatin-1 had pivotal roles in the progression of endometrial carcinomas. Immunohistochemical NUCB2 status may therefore serve as a potent biomarker for endometrial carcinomas.
Journal
-
- Endocrine Journal
-
Endocrine Journal 63 (3), 287-299, 2016
The Japan Endocrine Society
